Premas Biotech
Premas Biotech is dedicated to accelerating drug development through innovative technology platforms and a team of over 150 scientists and managers. Founded in 2005, the company has developed over 650 molecules and focuses on transforming drug discovery, vaccine development, and biotherapeutics. It collaborates globally to provide quality products and solutions for pharmaceutical and biotech companies, emphasizing speed, security, and cost-effectiveness. The company fosters an inclusive and innovative culture, with a focus on teamwork, learning, and long-term partnerships.
Industries
Nr. of Employees
medium (51-250)
Premas Biotech
13 High Field Lane, Madison, CT 06443, USA
Patents
Recombinant expression platform, constructs and methods for expression of difficult to express proteins (DTE-PS)
US-12559761-B2
View Details
Recombinant expression platform, constructs and methods for expression of difficult to express proteins (DTE-PS)
US-12559761-B2
View DetailsProducts
Recombinant diagnostic antigens
Purified recombinant viral and other antigens produced in yeast or bacterial hosts and supplied for research, ELISA and lateral-flow diagnostics.
Virus-like particle (VLP) vaccine candidate (preclinical)
Multi-antigen VLP vaccine candidate developed for oral and scalable delivery formats, progressed through preclinical evaluation.
Naive human scFv phage-display library
Large, diverse naive human single-chain variable fragment phage-display library available for antibody lead discovery.
Recombinant proteins and enzymes for alternative-food applications
Production of recombinant proteins, enzymes and ingredient biomolecules for alternative-food applications with strain development, process development, pilot and bulk manufacturing.
Recombinant diagnostic antigens
Purified recombinant viral and other antigens produced in yeast or bacterial hosts and supplied for research, ELISA and lateral-flow diagnostics.
Virus-like particle (VLP) vaccine candidate (preclinical)
Multi-antigen VLP vaccine candidate developed for oral and scalable delivery formats, progressed through preclinical evaluation.
Naive human scFv phage-display library
Large, diverse naive human single-chain variable fragment phage-display library available for antibody lead discovery.
Recombinant proteins and enzymes for alternative-food applications
Production of recombinant proteins, enzymes and ingredient biomolecules for alternative-food applications with strain development, process development, pilot and bulk manufacturing.
Services
Development and optimization of host strains and expression constructs for microbial, yeast and mammalian systems, including clone screening, vector selection and secretion/periplasmic expression strategies.
Early-stage evaluation services to identify expression strategies, host options and project feasibility prior to full development.
Comprehensive process development from shake flasks to pilot and commercial-scale bioreactors including media/feed optimization, clarification, chromatography, concentration, refolding and formulation development.
GMP-capable scale-up and manufacturing services, including technology transfer to contract manufacturers and continuous/semi-continuous process operation for gram-to-kilogram supply.
Analytical and bioanalytical assay development for identity, purity, potency and stability; execution of ELISA, neutralization assays, ADCC/CDC, HPLC, SDS-PAGE, MS and other orthogonal methods in support of development programs.
Development and optimization of host strains and expression constructs for microbial, yeast and mammalian systems, including clone screening, vector selection and secretion/periplasmic expression strategies.
Early-stage evaluation services to identify expression strategies, host options and project feasibility prior to full development.
Comprehensive process development from shake flasks to pilot and commercial-scale bioreactors including media/feed optimization, clarification, chromatography, concentration, refolding and formulation development.
GMP-capable scale-up and manufacturing services, including technology transfer to contract manufacturers and continuous/semi-continuous process operation for gram-to-kilogram supply.
Analytical and bioanalytical assay development for identity, purity, potency and stability; execution of ELISA, neutralization assays, ADCC/CDC, HPLC, SDS-PAGE, MS and other orthogonal methods in support of development programs.
Expertise Areas
- Protein biologics and antibody development
- Vaccine development (subunit, conjugate, VLP)
- Host strain engineering and cell line development
- Upstream and downstream bioprocess development and scale-up
Key Technologies
- Yeast expression systems (Pichia, Saccharomyces)
- Bacterial expression systems (E. coli, Bacillus)
- Mammalian expression systems (CHO, HEK)
- Phage-display scFv libraries
News & Updates
Premas Biotech has been awarded a project to develop a rotavirus VLP vaccine using its D-Crypt™ platform.
Premas Biotech has signed a licensing deal with Oravax Medical for COVID-19 vaccine technology in India.
Premas Biotech plans to start Phase 1 trials for its oral COVID-19 vaccine in South Africa.
Premas Biotech and Oravax Medical will test their oral VLP vaccine against the Omicron variant.
Premas Biotech has been awarded a project to develop a rotavirus VLP vaccine using its D-Crypt™ platform.
Premas Biotech has signed a licensing deal with Oravax Medical for COVID-19 vaccine technology in India.
Premas Biotech plans to start Phase 1 trials for its oral COVID-19 vaccine in South Africa.
Premas Biotech and Oravax Medical will test their oral VLP vaccine against the Omicron variant.